CEA recombinant adeno-associated virus, construction process thereof and applications

Abstract

The invention relates to a CEA recombined gland-associated viral vector, a method for constructing the same and an application of the same. The recombined gland-associated viral vector is obtained through replacing a gland-associated virus structural gene in a gland-associated viral vector by a carcinoembryonic antigen CEA gene or a recombined gland-associated viral vector obtained by the mutant gene of the CEA gene. The CEA recombined gland-associated viral vector can convey the wild type or mutant carcinoembryonic antigen gene carried by the vector into a monocyte-macrophage-dendritic cell line; moreover, cells carrying the specific antigen genes can be used to stimulate the effector cells of an immune system. Experiments show that CTL, which is induced by DC infected by the rAAV of the PSA recombined gland-associated viral vector, can effectively inhibit the growth of malignant cells, or kill tumor cells in the body of a patient; therefore, the CEA recombined gland-associated viral vector or products related to the recombined gland-associated viral vector can be used to make medicines used to cure breast carcinoma, cancer of colon, gastric cancer and adenocarcinoma of lung.

Description

technical field The present invention relates to a vector and its application, in particular to a recombinant adeno-associated virus vector and its construction method and its application in the preparation of antitumor drugs. Background technique The genetic structure of adeno-associated virus (AAV) has been identified. In 1983, Samulski et al. described the terminal repeat segment of AAV (upstream 5' end segment, downstream 3' end segment) (Samulski RJ, Srivastava A, Berns KI, Muzyczka N. Rescue of adeno-associated virus from recombinant plasmamids: gene correction within the terminal repeats of AAV. Cell. 33:135-143.). In 1984, Hermonat et al. described the low infectious particle (lip) gene and envelope (cap) gene of AAV (Hermonat PL, Labow MA, Wright R, Berns KI, Muzyczka N. Genetics ofadeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol. 51: 329-339. Hermonat, P.L., and Muzyczka, N. Use of adeno-associat...

AI Technical Summary

Problems solved by technology

However, rAAV still has some shortcomings, such as the instability of recombinant virus, low virus titer, and limited capacity for accepting therapeutic genes (generally, the maximum exogenous gene fragment that can be inserted is about 2000 base pairs (bp), otherwise the stability of rAAV sex will be destroyed)

Images